Microbiotica announced the first close of a GBP 36 million Series C on 16 October 2026. British Business Bank led the financing, joined by Tencent, IP Group, Cambridge Innovation Capital, Flerie Invest and Seventure Partners. The Cambridge company develops precision medicines based on defined combinations of gut bacteria. Proceeds will advance MB310, an oral capsule containing eight bacterial strains, into Phase 2 development for ulcerative colitis. The planned trial will test whether earlier clinical findings hold in a larger study. Founded in 2016 as a Wellcome Sanger Institute spinout, Microbiotica uses genomic analysis to connect bacterial signatures with patient outcomes.
Microbiotica secures GBP 36m Series C first close
British Business Bank leads funding for an ulcerative colitis study

Keep reading
More Funding

BrightAI secures USD 97 million to scale physical AI infrastructure
Smith Point Capital led the investment in sensor based monitoring for essential services.

Dcubed raises EUR 27.2 million to expand space hardware production
Warsaw Equity Group led the oversubscribed Series A plus round for the German manufacturer.

Linq raises USD 90 million to expand AI powered mobile infrastructure
Andreessen Horowitz led the Series B and partner Ben Horowitz joined the board.


